Datametrex AI Limited DM
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Avoid new buys; if already holding, consider reducing ahead of 2026-04-20 and reassess after clearer cash-flow evidence.
High risk from going concern doubt, working capital deficit and the shift to semi-annual reporting supports the reduce signal.
Sentiment remains negative with focus on the going concern doubt, large losses and reduced transparency from fewer reports.
SELL is the call. Neutral is the market mood. High risk means a lot can go wrong.
Latest change
- 29 Aug 2026 — Report released showing large losses and auditor going concern doubt, driving the negative trend shift.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
Datametrex AI Limited is a Canadian micro-cap combining AI healthcare software (EMR), data-center/infrastructure delivery, and payments patent licensing via Paymetrex. The company is in a restructuring/growth phase and remains unprofitable, with elevated dilution and execution risk. Price action and attention are driven mainly by small orders/licensing headlines rather than stable cash flows.
Bull case
Licensing deals via QuantIP could create a new revenue stream and trigger revaluation.
Bear case
Going concern doubt, large losses and reduced reporting increase dilution and liquidity risks.
Why this signal
High risk from going concern doubt, working capital deficit and the shift to semi-annual reporting supports the reduce signal.
Recent news
Datametrex has transitioned to semi-annual reporting under CBO 51-933. The annual report for the year ended 31 March 2026 showed a net loss of CAD 12.65 M and auditor Kingston Ross Pasnak LLP raised going concern doubts. The next report covers the period to 30 September 2026.